Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Vidal-Castiñeira, J.R. (Juan Ramón) | - |
dc.creator | Lopez-Vazquez, A. (Antonio) | - |
dc.creator | Martinez-Borra, J. (Jesús) | - |
dc.creator | Martinez-Camblor, P. (Pablo) | - |
dc.creator | Prieto, J. (Jesús) | - |
dc.creator | Lopez-Rodriguez, R. (Rosario) | - |
dc.creator | Sanz-Cameno, P. (Paloma) | - |
dc.creator | Vega, J. (Juan) de la | - |
dc.creator | Rodrigo, L. (Luis) | - |
dc.creator | Perez-Lopez, R. (Rosa) | - |
dc.creator | Perez-Alvarez, R. (Ramón) | - |
dc.creator | Lopez-Larrea, C. (Carlos) | - |
dc.date.accessioned | 2014-08-02T12:37:56Z | - |
dc.date.available | 2014-08-02T12:37:56Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Vidal-Castiñeira JR, López-Vázquez A, Martínez-Borra J, Martínez-Camblor P, Prieto J, López-Rodríguez R, et al. Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome. PLoS One. 2014 Jun 13;9(6):e99426 | es_ES |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://hdl.handle.net/10171/36214 | - |
dc.description.abstract | The aim of this study was to analyse the distribution of KIR haplotypes and the KIR2DL2/3 alleles in chronic HCV-infected patients in order to establish the influence on the response to pegylated interferon plus ribavirin classical treatment. The alleles study of previously associated KIR2DL2/3 showed that KIR2DL2*001 was more frequent in non-SVR (NSVR) (42.2% vs. 27.5%, p<0.05) and KIR2DL3*001 was associated with sustained viral response (SVR) (41.6% vs. 61.2%, p<0.005). The KIR2DL3*001-HLA-C1 association was also significant (24.5% vs. 45.7%, p<0.001). From the frequencies of KIR obtained, 35 genotypes were assigned on the basis of previous studies. The centromeric A/A genotype was more frequent in SVR (44.1% vs. 34.5%, p<0.005) and the centromeric B/B genotype was found to be significantly more frequent in NSVR (20.9% vs. 11.2%, p<0.001). The logic regression model showed the importance of KIR genes in predicting the response to combined treatment, since the positive predictive value (PPV) was improved (from 55.9% to 75.3%) when the analysis of KIR was included in addition to the IFNL3 rs12979860 polymorphism. The study of KIR receptors may be a powerful tool for predicting the combined treatment response in patients with chronic HCV infection in association with the determination of IFNL3 polymorphism. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Public Library of Science | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | KIR genotypes | es_ES |
dc.subject | KIR2DL2/3 alleles | es_ES |
dc.subject | Chronic HCV-infected patients | es_ES |
dc.subject | Pegylated interferon plus ribavirin | es_ES |
dc.subject | Treatment | es_ES |
dc.title | Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | http://dx.doi.org/10.1371/journal.pone.0099426 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.